- 360 WallStreet
- Posts
- Apes vs Shorts - epic meme battle 🤺
Apes vs Shorts - epic meme battle 🤺
Be the best prepared trader on the Street
Good day, 360!
Here are our TOP investing ideas today. These setups look primed! And don't forget to check out today's Economic Calendar. To your success!
SECO - 2nd day play, closed up 124% after announcing they would be transforming luxury goods operation models with AIGCC and ChatGPT Technologies
MYO - 30% higher in pre-market trade after MyoPro approved in Australia by National Disability Insurance Scheme
BBBY - Apes vs. Shorts: BBBY closes 92% higher, then falls 30% on $1B equity raise.
One Trade. One Stock. One Time.
There’s beauty in simplicity.
Narrowing 10,000 stocks down to one S&P 500 call or put option - at one scheduled time - is what traders of any experience need to eliminate confusion and maximize clarity.
This is Jeff Williams’ day-to-day in any market, catalyst or no catalyst.
Thousands of traders are alerted to Jeff's +40%, +70%, even +100% real-money trades of the day with tight stops and you’re next.
Because just for you? JW is slashing enrollment from $1599 to $799 to $599… to…only $29. That’s right! Only $29!
Review JW’s incredible Market Navigator special today as this offer will vanish quickly…
And new trades of the day drop at 9AM - don't miss another one!
SECO - 2nd day play, closed up 124% after announcing they would be transforming luxury goods operation models with AIGCC and ChatGPT Technologies
SECO was yesterday’s ChatGPT runner de jour. News PR’s with the words ChatGPT are sending low priced stocks soaring with plenty of trading opportunities galore. This is very akin to Bitcoin mania. Many of these will be fluff pieces but there will be great trading setups nonetheless. Companies that have real AI behind them such as C3.ai (ticker AI) continue higher and can run for days/weeks.
The $3.40/$3.50 area is an important pivot area this morning.
Above it SECO ran to $5 and had moves to $3.90 throughout the day.
This is an important demand area for a trade setup for a quick pop higher if buyers can come in.
Below $3.40 , targets to the downside are $3 and $2.50 if buyers walk and find a new shiny ChatGPT name today.
MYO - 30% higher in pre-market trade after MyoPro approved in Australia by National Disability Insurance Scheme
Myomo (MYO) has formed a nice base since December after selling off over 90% over the last 18 months. The CEO Paul Gudonis made some big purchases of 307,692 shares at an average price of $0.33, participating in the recent share offering.
Globis Capital Partners also announced a 7.2% stake on January 20. So there are some BIG insiders buying in recent weeks ahead of this announcement.
Given how much MYO has sold off, so long as insiders don’t dump into this news or once that selling is out of the way, there could be a nice short-term trade here. This new government approval could change the outlook for MYO.
$0.61-$0.6350 was an area of support in the after hours yesterday, and in the pre-market this morning so should be an important pivot level.
Above it, targets to the upside are $0.70, $0.75 and then pre-market highs at $0.80.
Below $0.61 there is potential support at $0.55, with a gap to fill at $0.5198 below that.
The company recently issued 20 million shares at $0.325 per share so this could be a liquidity event for investors who participated in that offering.
BBBY - Apes vs Shorts: BBBY closes 92% higher, then falls 30% on $1B equity raise
CVNA kicked off the meme madness last week, and yesterday the “Apes” came back for BBBY. However after the 92% move anyone still holding was met with a nasty surprise on the announcement of a $1 billion injection of equity in the after hours sending BBBY 30% lower on the incoming dilution.
BBBY traded over 276 million shares yesterday, more than enough to soak up those incoming shares and this cash injection should stave off bankruptcy at least in the near term, similar to what we saw with AMC last year.
So today will be an interesting battle between Shorts betting on bankruptcy and Apes looking to take this to the moon.
According to Finviz, over 45% of the float was short before this offering.
The $3.95/$4 area was a support level from yesterday and is so far holding in the pre-market as well.
Above it, targets to the upside are $4.80, $5.75 then $6.20.
Below $3.95, targets to the downside are $3.50, $3 and there is a gap to fill at $2.82 below that.
Economic Calendar (EST)
8:30am International Trade in Goods
8:55am Redbook Sales
12:00pm Jerome Powell
2:00pm Michael Barr
3:00pm Consumer Credit
4:30pm API Crude Oil Data
Earnings for Tuesday (after hours):
AAT, AIZ, AMCR, ATEN, ATO, BKH, CCK, CMG, CMP, CNO, CSL, CTLP, DEI, DHX, DLA, EEFT, EGP, EHC, ENPH, ENTA, EPM, ESS, EXEL, FMC, FRSH, FTNT, HIW, HMN, HRB, ICHR, ILMN, INNV, INSP, JKHY, KD, KREF, LPTV, LSK, LUMN, MODN, MTRX, NBR, NCR, NEWR, OMC, PAYC, PEAK, PLUS, PRU, QGEN, RAMP, RRR, RXO, SIMO, SNEX, SSNC, TCS, TENB, TESS, TRVG, USNA, VFC, VOYA, VRTX, VSAT, WERN, WU, YUMC, ZWS
Top Headlines
BBBY Bed Bath & Beyond Inc. Announces Proposed $225M Offering of Series A Convertible Preferred Stock and Warrants
BBBY Bed Bath and Beyond says will likely file for bankruptcy protection if stock offering fails – filing
BA Boeing To Slash About 2,000 White-Collar Jobs In Finance And HR - Seattle Times
AMBA Hyperview Selects Ambarella’s CV3-AD Family of Automotive AI Central Domain Controllers for Autonomous Driving High Performance Computing Platforms
INFY Infosys Collaborates with GE Digital to Deliver Energy Transition Solutions
PFE Continued strong Cresemba (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer
LVO LiveOne Debt Holders Exchange $21 Million for Preferred Shares Convertible at $2.10 per Share
BLNK: Proposed Public Offering of Common Stock -- $75Million .. BCS Bookmanager
KALV: KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session
GPK: Graphic Packaging Holding Company Reports Strong Fourth Quarter and Full Year 2022 Results; Strengthening Leadership in Fiber-Based Consumer Packaging with New Coated Recycled Paperboard Mill Investment
HUT: Hut 8 and US Bitcoin announce merger of equals to create a preeminent digital asset mining, hosting, managed infrastructure operations, and high-performance computing organization
VERO Venus Concept Announces Strategic Business Realignment to Accelerate Its Path to Long-Term, Sustainable, Profitability and Reports Preliminary Revenue Results for Fourth Quarter and Fiscal Year 2022
CREX: Creative Realities Confirms Receipt of Unsolicited Proposal from Pegasus Capital Advisors, L.P.
LIZI: LIZHI Drives Business Growth With AI-Powered Voice Technology and Explores AIGC Innovation
ALDX Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
KPRX: Kiora Pharmaceuticals Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases
SNDL: SNDL Expands Retail Network via Conclusion of Superette Group's CCAA Proceedings
INBS Intelligent Bio Solutions Inc. Announces Leading Food Industry Logistics Provider to Implement Fingerprint Drug Testing, Replacing Urine Testing
SQL SeqLL Establishes Two-year Cooperative Research and Development Agreement with U.S. Department of Justice's Federal Bureau of Investigation, Deal Terms Not Disclosed
BEEM: Beam Global Receives First Native Nation Order from The Confederated Tribes of Grand Ronde in Oregon
ONTX Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma
HYMC HYCROFT DRILLS 55 METERS OF 396.93 G/T SILVER in VORTEX
IRNT IronNet Signs Contract to Enhance Cybersecurity of U.S. Navy’s Naval Sea Systems Command (NAVSEA) Following Successful Pilot Program
LTBR: Study Validates Benefits of Lightbridge Designed Fuel Rods for Weapons-Grade Plutonium Disposition
IMMX: Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer
INDP: Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
If you are interested in advertising with 360, please contact us at [email protected]
Please see disclosures below.
62 Calef Hwy #233 Lee, New Hampshire 03861 United States
Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull
DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https://ragingbull.com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
Reply